Table 1.
Patient Characteristics (N=53)
| Characteristic | Value |
|---|---|
|
| |
| Recipient age, median in years (range) | 55 (20 – 71) |
|
| |
| Recipient sex, male, n (%) | 28 (53) |
|
| |
| Donor age, median in years (range) | 40 (20 – 70) |
|
| |
| Donor sex, male, n (%) | 28 (53) |
|
| |
| Disease type, n (%) | |
| Myeloid | 33 (62) |
| Acute myeloid leukemia | 15 (28) |
| Myelodysplastic syndrome | 10 (19) |
| Primary myelofibrosis | 5 (9) |
| Chronic myelogenous leukemia | 3 (6) |
| Lymphoid | 20 (38) |
| Non-Hodgkin lymphoma | 8 (15) |
| Acute lymphoblastic leukemia | 6 (11) |
| Chronic lymphocytic leukemia | 2 (4) |
| Hodgkin lymphoma | 2 (4) |
| Multiple myeloma/plasma cell leukemia | 2 (4) |
|
| |
| Graft source, n (%) | |
| Peripheral blood stem cells | 44 (83) |
| Bone marrow | 9 (17) |
|
| |
| Donor type, n (%) | |
| Sibling | 23 (43) |
| Unrelated | 30 (57) |
|
| |
| HLA compatibility, n (%) | |
| 8/8 match | 43 (81) |
| 7/8 match | 10 (19) |
|
| |
| Conditioning intensity, n (%) | |
| Myeloablative | 25 (47) |
| Reduced intensity | 28 (53) |
|
| |
| GVHD prophylaxis, n (%) | |
| Tacrolimus/methotrexate | 41 (77) |
| Cyclosporine/methotrexate | 8 (15) |
| Othera | 4 (8) |
|
| |
| Pre-transplant albumin, median (range) | 4.0 (3.0 – 4.7) |
|
| |
| Day-30 albumin, median (range) | 3.6 (1.8 – 4.6) |
|
| |
| Required TPN post-transplant, n (%) | 22 (41) |
GVHD, graft-versus-host disease; HLA, human leukocyte antigen; TBI, total body irradiation; TPN, total parenteral nutrition.
a
Tacrolimus/sirolimus (n=3), mycophenolate mofetil/prednisone (n=1)